98665-19-1
Chemical Structure
Ganoderic acid H
- CAS No.: 98665-19-1
- Formula:C32H44O9
- Molecular Weight:572.69
IUPAC Name: 6-(12-acetoxy-3-hydroxy-4,4,10,13,14-pentamethyl-7,11,15-trioxo-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-methyl-4-oxoheptanoic acid
InChIKey: YCXUCEXEMJPDRZ-UHFFFAOYSA-N
SMILES: CC(C)(C1C2)C(O)CCC1(C)C3=C(C4(C(CC(C4(C(OC(C)=O)C3=O)C)C(C)CC(CC(C)C(O)=O)=O)=O)C)C2=O
Biological Activity: Ganoderic acid H is a hydroxylated lanostane-type triterpenoid derived from Ganoderma lucidum with anticancer activity. Ganoderic acid H inhibits the constitutive transactivation activity of AP-1 and NF-κB; it also downregulates the secretion of uPA and the expression of CDK4, and suppresses the growth, adhesion, migration and invasion of cancer cells. Ganoderic acid H inhibits HIV-1 protease in vitro. Ganoderic acid H can be used in studies related to breast cancer and HIV infection[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ganoderic acid H | 99.68% | Ganoderic acid H is a hydroxylated lanostane-type triterpenoid derived from Ganoderma lucidum with anticancer activity. Ganoderic acid H inhibits the constitutive transactivation activity of AP-1 and NF-κB; it also downregulates the secretion of uPA and the expression of CDK4, and suppresses the growth, adhesion, migration and invasion of cancer cells. Ganoderic acid H inhibits HIV-1 protease in vitro. Ganoderic acid H can be used in studies related to breast cancer and HIV infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Jiang J, et al. Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling. International journal of molecular medicine. 2008 May;21(5):577-84. [Content Brief]
- [2]. Akbar R, et al. Interaction of ganoderic acid on HIV related target: molecular docking studies. Bioinformation. 2011;7(8):413-7.
- [3]. Ansari M H R, et al. Pharmacokinetic, Metabolomic, and Stability Assessment of Ganoderic Acid H Based Triterpenoid Enriched Fraction of Ganoderma lucidum P. Karst. Metabolites, 2022, 12(2):97.
